Dr. John Cassidy, Co-Founder and CEO of Cambridge Cancer Genomics (CCG.ai) was today named a Fellow of the Royal Society of Biology.
The Royal Society of Biology presents a single unified voice for biology: advising Government and influencing policy; advancing education; and engaging and encouraging public interest in the life sciences. The Society represents a diverse membership of individuals, learned societies and other organisations.
John Cassidy, CEO of CCG.ai says: “I am delighted to have been named a Fellow of the Royal Society of Biology. It’s an honour to be part of such a prestigious professional body. I hope, through my Fellowship, to have many opportunities to connect with the community and engage further with policy and government legislation.”
Fellowships are awarded to those who have made a prominent contribution to the advancement of the biological sciences. John was awarded for his leadership in directing CCG.ai’s commercial activities in the research and application of cancer genomics, specifically utilising AI to further the advancement of personalised medicine.
About Cambridge Cancer Genomics
Cambridge Cancer Genomics (CCG.ai) are on a mission to ensure that each patient has the right drug, at the right time, to beat their cancer. We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response.
We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance.
Find out more at www.ccg.ai
For more details, or to request an interview, please contact Press@CCG.ai